Dr. Oz's HealthCorp stock valuation drops 20% by end of 2026

Regulatory delays and enrollment struggles will erode investor confidence. A 20% decline in valuation reflects skepticism about HealthCorp's long-term viability amid prior authorization challenges.

Implied probability (Yes)

60%